0
selected
-
1.
Botulinum toxin injection to improve functional independence and to alleviate parenting stress in a child with advanced pantothenate kinase-associated neurodegeneration: A case report and literature review.
Lin, CI, Chen, KL, Kuan, TS, Lin, SH, Lin, WP, Lin, YC
Medicine. 2018;(20):e10709
-
-
Free full text
-
Abstract
RATIONALE Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive disease. Progressive motor symptoms such as dystonia and spasticity begin in childhood and relentlessly become incapacitating later in life. Treatments including anticholinergics and iron chelation are usually ineffective. Botulinum toxin type A (BoNT-A) is effective for adult patients with dystonia or spasticity. PATIENT CONCERNS We reported a 10-year-old female patient with advanced PKAN, manifesting as generalized dystonia and spasticity. DIAGNOSIS The patient was diagnosed with PKAN by a pediatric neurologist. INTERVENTIONS The patient received BoNT-A injection. OUTCOMES The effect was obvious at four weeks after the injection, with an improvement of 25% in Barry-Albright Dystonia Scale and 4% in Functional Independence Measure for Children score. Furthermore, there was a 3.8% reduction in Parenting Stress Index Short Form score and 8.3% improvement in Pain and Impact of Disability domain in the score of Cerebral Palsy Quality of Life for Children. LESSONS BoNT-A injection was effective to improve functional independence and to alleviate stress of caregivers in the patient with advanced PKAN.
-
2.
Emerging Treatments for Neuropathic Pain.
Pessoa, BL, Escudeiro, G, Nascimento, OJ
Current pain and headache reports. 2015;(12):56
Abstract
Neuropathic pain is a series of well-known conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of the pathophysiology of neuropathic pain, previously unexplored therapies have been used with encouraging results. As such, Acetyl-L-carnitine (ALC), Alpha-lipoic-acid (ALA), cannabinoids, Clonidine, EMA401, Botulinum Toxin type A, and new voltage-gated sodium channel blockers, can be cited. Furthermore, new modalities in neuromodulation such as high-frequency spinal cord stimulation, burst stimulation, dorsal root ganglion stimulation, transcranial direct current stimulation, and many others have been showing exciting results. Besides, changing paradigms may occur with the advent of optogenetics and a better understanding of epigenetic regulation. This article reviews the published literature on the treatment of NP. Despite the interesting results, randomized controlled trials are demanded for the majority of the therapies previously mentioned.
-
3.
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
Young, CA, Ellis, C, Johnson, J, Sathasivam, S, Pih, N
The Cochrane database of systematic reviews. 2011;(5):CD006981
Abstract
BACKGROUND Motor neuron disease (MND), also known as amyotrophic lateral sclerosis, is a progressive, neurodegenerative condition which may cause dysphagia, as well as limb weakness, dysarthria, emotional lability and respiratory failure. Since normal salivary production is 0.5 to 1.5 litres daily, loss of salivary clearance due to dysphagia leads to salivary pooling and sialorrhea, often resulting in distress and inconvenience to patients. OBJECTIVES To systematically review evidence on treatment of sialorrhea in MND, including medications, radiotherapy and surgery. SEARCH STRATEGY We searched the Cochrane Neuromuscular Disease Group Specialized Register (1 October 2010), the Cochrane Central Register of Controlled Trials )(CENTRAL) (The Cochrane Library issue 3, 2010), MEDLINE (January 1966 to September 2010), EMBASE (January 1980 to September 2010), AMED (1985 to September 2010) and CINAHL Plus (January 1937 September 2010). All bibliographies of the identified randomized trials were reviewed and authors contacted as needed. Known experts in the field were contacted to identify further published and unpublished papers. SELECTION CRITERIA We included randomized and quasi-randomised controlled studies on any intervention for sialorrhea and related symptoms, in people with MND. DATA COLLECTION AND ANALYSIS Review authors summarised data independently in a customised data collection form and confirmed data presented in Cochrane Review Manager software. MAIN RESULTS Only one randomized controlled trial was identified. This was a well designed study of botulinum toxin B injected into parotid and submandibular glands of 20 patients, which showed positive results for four weeks (Jackson 2009). There was low risk of bias in the study and no significant adverse events reported. AUTHORS' CONCLUSIONS There is some evidence for use of botulinum toxin injections to salivary glands for the treatment of sialorrhea in MND. Further research is required on this important symptom. Data are needed on the problem of sialorrhea in MND and its measurement, both by patient self report measures and objective tests. These will allow the development of better randomized controlled trials.
-
4.
Esophageal motility disorders: medical therapy.
Lacy, BE, Weiser, K
Journal of clinical gastroenterology. 2008;(5):652-8
Abstract
Symptoms of chest pain and dysphagia are common in the adult population. Most patients initially undergo an evaluation to exclude anatomic causes (ie, esophagitis, stricture) and cardiovascular disease as the etiology of these symptoms. Patients with persistent symptoms may then be referred for specialized testing of the esophagus, including esophageal manometry. Disorders of esophageal motility, which include achalasia, diffuse esophageal spasm, nutcracker esophagus, hypertensive lower esophageal sphincter, and ineffective motility are often identified in these patients. Unfortunately, the etiology of these disorders has not been well characterized and the treatment has not been standardized. This review will briefly discuss the impact, etiology, and diagnosis of esophageal motility disorders, and then focus on the medical management of these disorders using evidence from well-designed, prospective studies, where available.
-
5.
Bowel management for patients with myelodysplasia.
Doolin, E
The Surgical clinics of North America. 2006;(2):505-14, xi
-
6.
Botulinum toxins in dentistry--the new paradigm for masticatory muscle hypertonicity.
Katz, H
Singapore dental journal. 2005;(1):7-12
Abstract
A variety of factors, such as stress, hormones, diet, drugs, trauma, and certain neuromuscular diseases, can lead to an increase in sympathetic muscle tone, which results in masticatory muscle hypertonicity and parafunction. Dentists have traditionally attempted to treat and prevent this transient disease with methods that are expensive, risky, irreversible, and not evidence-based. There is a need for a conservative reversible noninvasive treatment that is quick, easy, relatively inexpensive, long acting, and effective. Botulinum toxin, a natural protein, is one of the most potent biological substances known. Masticatory muscle relaxation can be reliably achieved by injecting measured doses of botulinum toxin into specific sites in the major muscles of mastication. A reduction in dystonia and pain with optimization of function is easily achievable with a site- and dose-specific injection protocol. The use of botulinum toxin offers the dentist an extremely effective tool to add to the armamentarium for treating conditions that derive from masticatory and other pericranial muscular conditions, and offers the general dentist who is not an expert in gnathology and occlusion a safe, effective treatment for controlling the symptoms of masticatory muscle hypertonicity.
-
7.
Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review.
Chiu, MJ, Chang, YC, Hsiao, TY
Dysphagia. 2004;(1):52-7
Abstract
Cricopharyngeus (CP) muscle spasm can lead to severe dysphagia. Myotomy of the CP muscle was the treatment of choice. Recently, botulinum toxin type A (BtxA) has been used for CP spasm. It usually brings improvement in deglutition but most patients require reinjection in 3-5 months. We report a 35-year-old man who had an arteriovenous malformation hemorrhage in the brain stem resulting in CP spasm and consequently severe dysphagia. He received BtxA injection and deglutition and nutrition remained good one year after treatment. A literature review analyzing 28 patients and our patient showed negative correlations between age and BtxA dose and between age and duration. Efficacy was positively correlated with duration and BtxA dose was positively correlated with pretreatment severity. In conclusion, physicians would use higher doses on patients with more severe cases but use lower doses on older patients. Those who obtained better post-treatment results would enjoy longer effective duration. Thus, the effective duration of the BtxA is multifactorial.